Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug443 | BAY1237592 Wiki | 1.00 |
| drug2483 | NO gas Wiki | 1.00 |
| drug2772 | PH-combination therapy Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006976 | Hypertension, Pulmonary NIH | 0.50 |
| D006973 | Hypertension NIH | 0.20 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002092 | Pulmonary arterial hypertension HPO | 0.50 |
| HP:0000822 | Hypertension HPO | 0.20 |
Navigate: Correlations HPO
There is one clinical trial.
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure affecting the blood vessels in the lungs due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Pulmonary hypertension is characterized by the elevation of pressure in the pulmonary arteries (PAP) and of the pulmonary vascular resistance (PVR) leading to increased workload of the right chamber of the heart to eject blood against this elevated resistance. The goal of this study is to measure the safety and tolerability of the drug as well as the reduction of the PVR at different doses In Part A patients without specific treatment for PH (untreated patients) will be tested. In Part B patients stably pretreated with specific PH drugs will be studied in combination with the new inhaled drug
Description: PVR = 80* (PAP - PCWP) / CO (dyn·sec·cm-5) PAP = pulmonary arterial pressure PCWP = pulmonary capillary wedge pressure CO = cardiac output
Measure: Peak percent reduction in PVR (Pulmonary vascular resistance) from "baseline 2" for untreated patients Time: Up to 5 hours post inhalation of BAY1237592 compared to "baseline 2"Description: PVR = 80* (PAP - PCWP) / CO (dyn·sec·cm-5)
Measure: Peak percent reduction in PVR from "baseline" for pre-treated patients Time: Up to 5 hours post inhalation of BAY1237592 compared to "baseline"Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports